Home 
Bratislava Medical Journal 2015 Bratislava Medical Journal Vol.116, No.1, p.69-73, 2015
Bratislava Medical Journal 2015 Bratislava Medical Journal Vol.116, No.1, p.69-73, 2015
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Ekologia - Ecology Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudba 2025Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.116, No.1, p.69-73, 2015 |
||
| Title: Tamoxifen and tranilast show a synergistic effect against breast cancer in vitro | ||
| Author: S. Darakhshan, A. Ghanbari, F. Gholami Rad, A. Bidmeshki Pour | ||
| Abstract: Objective: This study was aimed at examining a separate or combined effect of tamoxifen and tranilast drugs on growth and proliferation of breast cancer cells. Background: Breast cancer is one of the most common cancers and the second leading cause of cancer death among women worldwide. Tamoxifen is the most widely used anti-estrogen for the treatment of breast cancer. Studies show that a combination therapy with other drugs enhances the activity of tamoxifen. Tranilast is an anti-inflammatory drug. We hypothesize that tranilast plus tamoxifen can work synergistically and help getting better result from this anticancer drug. Methods: Two breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with graduated concentrations of tamoxifen and tranilast alone or in combination at 24, 48 or 72 hours for MCF-7, and 48 hours for MDA-MB-231 cells. We used the MTT assay and lactate dehydrogenase leakage (LDH) assay to evaluate cell viability and cytotoxicity, respectively. Results: In both ER-positive and ER-negative breast cancer cell lines, the combination of tranilast and tamoxifen was more effective in growth inhibition than single drug exposure. Conclusion: We have demonstrated that by means of a synergistic/additive inhibitory effect, tranilast was capable of enhancing the in vitro activity of tamoxifen on breast cancer cell lines. Based on the results obtained in this study, tranilast could be a candidate drug for combination therapy in resistant breast cancer patients (Fig. 9, Ref. 17). |
||
| Keywords: breast cancer, Tamoxifen, Tranilast, LDH release, MTT. | ||
| Year: 2015, Volume: 116, Issue: 1 | Page From: 69, Page To: 73 | |
| doi:10.4149/BLL_2015_013 |
||
|
|
 download file |
|